Oct. 16 at 1:37 PM
📉
$BDX under pressure. Shares slid in premarket after CFO Chris DelOrefice announced his exit, even as Becton Dickinson posted strong year-end results.
💰 Q4 revenue climbed 8.3% YoY to
$5.9B, with full-year sales hitting
$21.8B, but the surprise leadership change spooked investors. DelOrefice leaves Dec 5, with Vitor Roque, a 20-year BD veteran, stepping in as interim CFO.
🏥 The timing couldn’t be worse—U.S. regulators just launched a medical-device import probe, slamming medtech stocks across the board. That, plus the CFO shuffle, sent
$BDX down ~6% after hours and another 1% premarket.
📊 Despite the selloff, analysts stay bullish with an average price target of
$208—roughly 15% upside from current levels. But with leadership uncertainty and sector pressure, investors are treading carefully heading into the Nov 6 earnings call.
